Huntington's Disease (HD) Models

Wild Mouse 750
Wild Mouse 750
Human Xenograft Models
Cell Derived Xenograft Models
Autoimmune Disease Models
Autoimmune Nephropathy modelsAcute Lung Injury ModelsIdiopathic Pulmonary Fibrosis ModelsSjögren’ s Syndrome ModelsSystemic Lupus Erythematosus (SLE) ModelsMultiple Sclerosis ModelsRheumatoid Arthritis ModelsPsoriasis ModelsInflammatory Bowel Disease ModelsAtopic Dermatitis Models Asthma Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsMASH ModelsHyperlipidemia ModelsOsteoporosis ModelsHyperuricemia Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765
Rare Disease Mouse Models
Progressive Muscular Dystrophy ModelsHemophilia A Models
Neurodegenerative Disease Mouse Models
Alzheimer’s Disease (AD) ModelsParkinson’s Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) Models
Immuno-Oncology Mouse Models
Human Xenograft ModelsHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models

Huntington's disease (HD), also known as Huntington's chorea, is a rare autosomal dominant basal ganglia disease that occurs mainly in the middle-aged and elderly population, with slowly progressive exacerbations that can eventually lead to death. HD is caused by mutations in the huntingtin gene (HTT), located on the short arm of chromosome 4. The gene contains a polymorphic trinucleotide repeat expansion, CAG repeats of cytosine-adenine-guanine. A series of CAG repeats results in the production of a polyglutamine tract (or polyQ tract). When the number of CAG repeats exceeds 40, there is an abnormal amplification of glutamines in the polyQ region. This leads to the misfolding of HTT protein fragments, which interact with a substantial number of proteins and accumulate in the nucleus and nerve terminals, causing neuronal damage and affecting a wide region of the brain.

Although the genetic pathogenesis of HD has been demonstrated since 1993, there are currently no effective treatments to halt the disease's progression. GemPharmatech has developed HD models that can simulate the clinical symptoms and dysfunctional phenotypes of HD to help assess the efficacy and safety of potential HD therapies.

Strain No.
 Strain Name Strain Type Description
T054804 B6-hHTT130-N Transgenic GemPharmatech has developed the B6-hHTT CAG130 model, in which the N-terminal of human HTT gene with 130 consecutive CAG repeats was introduced into the mouse genome. The model is expected to simulate Huntington's disease's (HD) pathological characteristics and functional deficits, making it suitable for screening and safety evaluation for potential HD therapies.